 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | 131-I Apamistamab/CAR T-cell (Iomab-ACT) / Actinium
Trial completion date, Trial primary completion date, CAR T-Cell Therapy: MED20-165: Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Dec 15, 2023
P1, N=6, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
- Nplate (romiplostim) / Amgen, Kyowa Kirin
Low-Dose Targeted Radioimmunotherapy (Iomab-ACT) Achieves Lymphocyte and Monocyte Depletion Prior to CD19-Targeted CAR T-Cell Therapy for Relapsed of Refractory B-Cell ALL or DLBCL with Minimal CRS and Icans () - Dec 11, 2023 - Abstract #TCTASTCTCIBMTR2024TCT_ASTCT_CIBMTR_876;
P1
Low-dose Iomab-ACT prior to 19-28z CAR-T depletes peripheral lymphocytes/monocytes and has minimal non-hematologic toxicity (including CRS/ICANS); cytopenias requiring blood product/growth factor support can occur in the weeks post-CAR-T. This pilot continues to enroll pts.
- | 131-I Apamistamab/CAR T-cell (Iomab-ACT) / Actinium
Trial completion date, Trial primary completion date, CAR T-Cell Therapy: MED20-165: Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Jul 28, 2023
P1, N=6, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
This pilot continues to enroll pts. Trial completion date: Jan 2024 --> Jan 2025 | Trial primary completion date: Jan 2024 --> Jan 2025
- || 131-I Apamistamab/CAR T-cell (Iomab-ACT) / Actinium
Could $atnm iomab-ACT help here? (Twitter) - Jun 2, 2023
- Iomab-B (I-131-apamistamab) / Actinium, Immedica
An Ongoing Pilot Study of Targeted Radioimmunotherapy (131-I Apamistamab) Conditioning Prior to CD19-Targeted CAR T-Cell Therapy for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma (Hall D (Ernest N. Morial Convention Center)) - Nov 4, 2022 - Abstract #ASH2022ASH_6475;
P1
Within the last year alone, the FDA approved brexu-cel for adults w/ R/R B-ALL and expanded indications for liso-cel and axi-cel to include DLBCL w/ primary refractory disease or early first relapse...Anti-cytokine therapies beyond tocilizumab (anti-IL-6R mAb) are being investigated for prevention of CRS/ICANS, including lenzilumab (anti-GM-CSF mAb) and anakinra (IL-1R antagonist)...Accordingly, we designed and initiated a pilot study of Iomab-B w/ adoptive cellular therapy (Iomab-ACT; Fig 1A).Study design and Iomab-ACT is a single-institution pilot study of Iomab-B (w/o chemotherapy) as conditioning prior to 19-28z CAR-T in adults w/ R/R B-ALL or DLBCL (NCT04512716)...Unexpected toxicity (given low dose of ARC) observed in 1 pt included severe trilineage cytopenias lasting >8 wks (requiring RBC/PLT transfusion support, G-CSF, romiplostim) w/o marrow hypoplasia and w/o other apparent neoplastic or drug-induced etiology; this met criteria for dose-limiting toxicity and we will monitor in the next 3 pts...Key exploratory objectives include describing changes in circulating immune cells following ARC and 19-28z CAR T-cells w/spectral cytometry using a custom antibody panel (Fig 1B) and cytokine levels in cerebrospinal fluid. We hope to generate preliminary data to guide further study of CD45-targeted ARCs prior to CAR-T and other forms of adoptive cellular therapy.
- | 131-I Apamistamab/CAR T-cell (Iomab-ACT) / Actinium
Trial completion date, Trial primary completion date, CAR T-Cell Therapy: MED20-165: Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Oct 28, 2022
P1, N=6, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
We hope to generate preliminary data to guide further study of CD45-targeted ARCs prior to CAR-T and other forms of adoptive cellular therapy. Trial completion date: Jan 2023 --> Jan 2024 | Trial primary completion date: Jan 2023 --> Jan 2024
- || 131-I Apamistamab/CAR T-cell (Iomab-ACT) / Actinium
We were focusing more on high-impact talks and themes from ASH 2021 but once we have more data from Iomab-ACT we'll be happy to share in the appropriate forum. (Twitter) - Mar 19, 2022
- || 131-I Apamistamab/CAR T-cell (Iomab-ACT) / Actinium
Will you be able to discuss any details related to Iomab-ACT? (Twitter) - Mar 18, 2022
- 131-I Apamistamab/CAR T-cell (Iomab-ACT) / Actinium
Iomab with Adoptive Cellular Therapy (Iomab-ACT): A Pilot Study of 131-I Apamistamab Followed By CD19-Targeted CAR T-Cell Therapy for Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma () - Nov 24, 2021 - Abstract #ASH2021ASH_6347;
P1
If dose-limiting toxicity (severe infusion-related reactions, treatment-resistant severe CRS/ICANS, persistent regimen-related cytopenias, among others defined in protocol) is seen in 0-1 of the first 3 pts treated, then up to 6 total (up to 3 additional) pts will be treated. We have designed this study to provide preliminary data to support further investigation of CD45-targeted ARCs prior to adoptive cellular therapy.
- || 131-I Apamistamab/CAR T-cell (Iomab-ACT) / Actinium
Hopeful CAR-T plus Iomab-ACT lymphodepletion will be superior to Auto @MarkGeyerMD (Twitter) - Sep 28, 2021
- ||| 131-I Apamistamab/CAR T-cell (Iomab-ACT) / Actinium
Minimal residual disease: Curious too about MRD negativity benefit with Iomab-ACT... (Twitter) - Sep 11, 2021
- || 131-I Apamistamab/CAR T-cell (Iomab-ACT) / Actinium
Also watching closely Iomab-ACT trial investigated by @MarkGeyerMD for ARC lymphodepletion prior to CAR-T. Preclinical data show promise in significantly reducing CRS and Neurotoxicity. First human dose earlier this year with data expected soon (Twitter) - Sep 11, 2021
- ||| 131-I Apamistamab/CAR T-cell (Iomab-ACT) / Actinium
This looks very interesting. For this hard to treat group, do you think combining w/ ARC preconditioning regimen would be beneficial? Closely watching Iomab-ACT @MarkGeyerMD CAR-T preconditioning for r/r DLBCL and look forward to data at ASH (Twitter) - Aug 5, 2021
- || 131-I Apamistamab/CAR T-cell (Iomab-ACT) / Actinium, lenzilumab (KB003) / Humanigen, Emergent Biosolutions, Telcon
Dr. Geyer, is it correct to say Lenzilumab is a therapeutic while Iomab-ACT is a prophylactic? If so, do you think there could be a need for both in CAR-T? (Twitter) - May 20, 2021
- || 131-I Apamistamab/CAR T-cell (Iomab-ACT) / Actinium
Thank you. Yes, this is one of many approaches being investigated, including in our ongoing Iomab-ACT study. (Twitter) - May 8, 2021
- |||| 131-I Apamistamab/CAR T-cell (Iomab-ACT) / Actinium
Preclinical: Hi Professor, great article! How might novel preconditioning regimens like ARCs relate to your research? Iomab-ACT (NCT04512716) is being studied by @MarkGeyerMD @ MSK & shows preclinical promise in eliminating CRS, neurotoxicity, & permanent myelosuppression (Twitter) - May 6, 2021
P1
- || 131-I Apamistamab/CAR T-cell (Iomab-ACT) / Actinium
Thoughts on conditioning prior to Car-T? I’m big on Iomab-ACT. #atnm (Twitter) - Apr 14, 2021
- | 131-I Apamistamab/CAR T-cell (Iomab-ACT) / Actinium
Trial completion date, Trial primary completion date, CAR T-Cell Therapy: MED20-165: Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Mar 16, 2021
P1, N=6, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
We have designed this study to provide preliminary data to support further investigation of CD45-targeted ARCs prior to adoptive cellular therapy. Trial completion date: Jan 2022 --> Jan 2023 | Trial primary completion date: Jan 2022 --> Jan 2023
- || 131-I Apamistamab/CAR T-cell (Iomab-ACT) / Actinium
Enrollment open, CAR T-Cell Therapy: MED20-165: Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Feb 10, 2021
P1, N=6, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial completion date: Jan 2022 --> Jan 2023 | Trial primary completion date: Jan 2022 --> Jan 2023 Not yet recruiting --> Recruiting
- | 131-I Apamistamab/CAR T-cell (Iomab-ACT) / Actinium
Trial completion date, Trial initiation date, Trial primary completion date, CAR T-Cell Therapy: MED20-165: Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Dec 17, 2020
P1, N=6, Not yet recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Not yet recruiting --> Recruiting Trial completion date: Aug 2021 --> Jan 2022 | Initiation date: Oct 2020 --> Jan 2021 | Trial primary completion date: Aug 2021 --> Jan 2022
- || 131-I Apamistamab/CAR T-cell (Iomab-ACT) / Actinium
Also, still early days, but Iomab-ACT prior to CAR-T therapy with @MarkGeyerMD as Principal Investigator seems promising in terms of eliminating CRS and neurotoxicity! (Twitter) - Dec 5, 2020
- |||| 131-I Apamistamab/CAR T-cell (Iomab-ACT) / Actinium
CAR T-Cell Therapy: $ATNM Iomab-ACT targeted conditioning with a CD19 CAR T-Cell Therapy. The 29 months Follow up the CR is 83%, 5 yr follow up the CR 50%. Better than $CSRP & $ALLO (Twitter) - Oct 27, 2020
- || 131-I Apamistamab/CAR T-cell (Iomab-ACT) / Actinium
New P1 trial, CAR T-Cell Therapy: MED20-165: Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Aug 12, 2020
P1, N=6, Not yet recruiting, Sponsor: Memorial Sloan Kettering Cancer Center